Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 21 11 2023
revised: 15 01 2024
accepted: 01 02 2024
medline: 18 3 2024
pubmed: 12 2 2024
entrez: 11 2 2024
Statut: ppublish

Résumé

We present England 2021/22 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related emergency care use in children aged 1-17 and in adults aged 50+, and serological findings in vaccinated vs unvaccinated adults by hemagglutination inhibition assay. Influenza vaccination has been routinely offered to all children aged 2-10 years and adults aged 65 years + in England. In 2021/22, the offer was extended to children to age 15 years, and adults aged 50-64 years. Influenza activity rose during the latter half of the 2021/22 season, while remaining comparatively low due to COVID-19 pandemic control measures. Influenza A(H3N2) strains predominated. A test negative design was used to estimate aVE by vaccine type. Cases and controls were identified within a sentinel laboratory surveillance system. Vaccine histories were obtained from the National Immunisation Management Service (NIMS), an influenza and COVID-19 vaccine registry. These were linked to emergency department presentations (excluding accidents) with respiratory swabbing ≤ 14 days before or ≤ 7 days after presentation. Amongst adults, 423 positive and 32,917 negative samples were eligible for inclusion, and 145 positive and 6,438 negative samples among children. Those admitted to hospital were further identified. In serology against the circulating A(H3N2) A/Bangladesh/4005/2020-like strain, 61 % of current season adult vaccinees had titres ≥ 1:40 compared to 17 % of those unvaccinated in 2020/21 or 2021/22 (p < 0.001). We found good protection from influenza vaccination against influenza requiring emergency care in children (72.7 % [95 % CI 52.7, 84.3 %]) and modest effectiveness in adults (26.1 % [95 % CI 4.5, 42.8 %]). Adult VE was higher for A(H1N1) (81 % [95 % CI 50, 93 %]) than A(H3N2) (33 % [95 % CI 6, 53 %]). Consistent protection was observable across preschool, primary and secondary school aged children. Imperfect test specificity combined with very low prevalence may have biased estimates towards null. With limited influenza circulation, the study could not determine differences by vaccine types.

Identifiants

pubmed: 38342716
pii: S0264-410X(24)00150-6
doi: 10.1016/j.vaccine.2024.02.006
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Influenza Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1656-1664

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Heather J Whitaker (HJ)

Statistics, Modelling and Economics Department, UK Health Security Agency, Colindale, London, UK. Electronic address: heather.whitaker@ukhsa.gov.uk.

Katie Hassell (K)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Katja Hoschler (K)

Virus Reference Unit, UK Health Security Agency, Colindale, London, UK.

Linda Power (L)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Julia Stowe (J)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Nicki L Boddington (NL)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Camille Tsang (C)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Hongxin Zhao (H)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Ezra Linley (E)

Seroepidemiology Unit, UK Health Security Agency, Manchester, UK.

Elizabeth Button (E)

Nuffield Department of General Practitioners Research and Surveillance Centre, Oxford Primary Care Health Sciences, University of Oxford, Oxford, UK.

Cecilia Okusi (C)

Nuffield Department of General Practitioners Research and Surveillance Centre, Oxford Primary Care Health Sciences, University of Oxford, Oxford, UK.

Carole Aspden (C)

Nuffield Department of General Practitioners Research and Surveillance Centre, Oxford Primary Care Health Sciences, University of Oxford, Oxford, UK.

Rachel Byford (R)

Nuffield Department of General Practitioners Research and Surveillance Centre, Oxford Primary Care Health Sciences, University of Oxford, Oxford, UK.

Simon deLusignan (S)

Nuffield Department of General Practitioners Research and Surveillance Centre, Oxford Primary Care Health Sciences, University of Oxford, Oxford, UK; Royal College of General Practitioners Research and Surveillance Centre, 30, Euston Square, London, UK.

Gayatri Amirthalingam (G)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Maria Zambon (M)

Virus Reference Unit, UK Health Security Agency, Colindale, London, UK.

Nick J Andrews (NJ)

Statistics, Modelling and Economics Department, UK Health Security Agency, Colindale, London, UK; Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Conall Watson (C)

Immunisation and Vaccine-preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH